Core Insights - The new medical insurance directory, effective from January 1, 2025, includes three innovative drugs developed by Kelun-Biotech, namely Lukanasatuzumab (Jiatailai), Cetuximab N01 (Daitailai), and Tagolizumab (Ketailai) [1][2] - Lukanasatuzumab is the first domestically developed ADC approved for treating advanced triple-negative breast cancer (TNBC) and has received approval for a second indication for EGFR mutation-positive non-small cell lung cancer (NSCLC) [1] - The inclusion of these drugs in the medical insurance directory significantly reduces treatment costs and alleviates the financial burden on patients, making life-saving treatments more accessible [2] Company Insights - Kelun-Biotech's CEO, Dr. Ge Junyou, emphasized the company's commitment to addressing unmet clinical needs and providing affordable alternatives to existing treatments, aiming to prevent poverty caused by medical expenses [2] - The company positions itself as a leader in innovative drug development, focusing on filling gaps in treatment options for serious conditions [1][2] Industry Insights - The new insurance directory reflects a broader trend in the healthcare industry towards making innovative treatments more accessible through reimbursement mechanisms [2] - The approval of Lukanasatuzumab and its subsequent indications highlights the growing importance of domestic pharmaceutical innovation in addressing critical healthcare challenges in China [1]
新版国家医保目录今日起实施 科伦博泰生物-B三款创新药惠及患者